SCHEMBL4438770

SCHEMBL4438770

COC(=O)c1cccn(Cc2ccccc2-c2ccccc2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.53
LMNA P02545 3/20 0.53
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
BRD4 O60885 2/20 0.48
BRD2 P25440 1/20 0.48
BRD3 Q15059 1/20 0.48
BRDT Q58F21 1/20 0.48
GABRA1 P14867 2/20 0.47
GABRG2 P18507 2/20 0.47
GABRB3 P28472 2/20 0.47
GABRA3 P34903 2/20 0.47
SLC6A3 Q01959 3/20 0.47
SLC6A4 P31645 2/20 0.47
THRB P10828 1/20 0.46
POLB P06746 1/20 0.46
TP53 P04637 2/20 0.46
RXFP1 Q9HBX9 2/20 0.46
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4994050 0.92 SLC6A3 (0.60) MAPTLMNAALDH1A1KDM4EBRD4
SCHEMBL4993706 0.86 SLC6A3 (0.60) MAPTLMNAALDH1A1KDM4EBRD4
SCHEMBL4986527 0.85 BRD4 (0.47) MAPTLMNAALDH1A1KDM4EBRD4
SCHEMBL4992594 0.83 MAPT (0.49) MAPTLMNAALDH1A1KDM4EBRD4
SCHEMBL4987882 0.82 BRD4 (0.57) MAPTLMNAALDH1A1KDM4EBRD4
SCHEMBL4997088 0.82 ALDH1A1 (0.57) MAPTLMNAALDH1A1KDM4EBRD4
SCHEMBL4992963 0.82 BRD4 (0.60) MAPTALDH1A1KDM4EBRD4BRD2
SCHEMBL1137191 0.81 BRD4 (0.70) MAPTLMNAALDH1A1KDM4EBRD4
SCHEMBL4553728 0.80 MAPK8 (0.53) MAPTLMNAALDH1A1KDM4EBRD4
SCHEMBL4997385 0.79 MAPT (0.61) MAPTLMNAALDH1A1KDM4EBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 MAPT 4654/4885LMNA 809/4885ALDH1A1 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.